id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-347871-w6274bdg	Kloc, Malgorzata	The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients	2020-07-31		.txt	text/plain	612	42	45	These drugs, through the inhibition of the RhoA/actin-dependent expression of virus receptors in the macrophages and macrophage recruitment to the lungs, have the potential to inhibit cytokine storm of long macrophages, reduce or eliminate ARDS and improve the outcome of COVID-19 infection. In our search for clinically applicable RhoA pathway inhibitors we found that drugs clinically approved for the treatment of multiple sclerosis (MS), Fingolimod and Siponimod, also inhibit RhoA and RhoA/actin-dependent macrophage receptors recycling, and expression, and can be potentially used as an anti-chronic rejection therapy in human transplantation (11, 12) . Because these clinically approved drugs inhibit, via RhoA/ actin pathway, macrophage movement, and expression of macrophage receptors, they have also a potential to inhibit ACE2 receptors expression and the recruitment of macrophages to the lungs of the COVId-19 patients, which in turn would decrease cytokine storm and attenuate ARDS. Macrophage/monocyte-specific deletion of RhoA down-regulates fractalkine receptor and inhibits chronic rejection of mouse cardiac allografts	./cache/cord-347871-w6274bdg.txt	./txt/cord-347871-w6274bdg.txt